Latest Breaking News On - Johan dighed - Page 3 : comparemela.com

Karolinska Development s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration | 04 12 23

Karolinska Development s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration | 04 12 23
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesKarolinska institutetJohan dighedEmily jutkiewiczViktor drvotaUniversity of michiganKarolinska development ab nasdaq stockholmProfessor amynah pradhan at washington universityUs national institute of drug abuseKarolinska developmentNasdaq stockholmDrug abuseDelta opioid receptor agonistProfessor amynah pradhanWashington universityGeneral counsel

Karolinska Development s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration

Karolinska Development s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United statesEmily jutkiewiczViktor drvotaKarolinska institutetJohan dighedUs national institute of drug abuseProfessor amynah pradhan at washington universityUniversity of michiganKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmDrug abuseDelta opioid receptor agonistProfessor amynah pradhanWashington universityGeneral counsel

Karolinska Development s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis

Karolinska Development s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Viktor drvotaKarolinska institutetJohan dighedKarolinska developmentLiver internationalKarolinska development ab nasdaq stockholmNasdaq stockholmUmecrine cognitionGeneral counsel

Karolinska Development s portfolio company Modus Therapeutics raises capital to expand the development program for sevuparin

STOCKHOLM, SWEDEN November 8, 2023. Karolinska Development AB today announces that its portfolio company Modus Therapeutics has decided to carry out a rights issue that can raise up to approximately.

Karolinska institutetViktor drvotaJohan dighedKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmModus therapeuticsNasdaq first north growth marketModus therapeuticVolume weighted average priceGeneral counsel

Karolinska Development s portfolio company Modus

STOCKHOLM, SWEDEN November 8, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has.

Karolinska institutetJohan dighedViktor drvotaKarolinska developmentKarolinska development ab nasdaq stockholmNasdaq stockholmModus therapeuticsNasdaq first north growth marketModus therapeuticVolume weighted average priceGeneral counselStockholm stock exchange kdevArolinska development ab publ